Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Inclusion Criteria: * Patients must be ≥ 18 years of age * Patients with histologically diagnosed relapsed high grade serous ovarian cancer (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease \>6 months (\>/=183 days) after completion of their last platinum therapy. * Documented germline mutation in Breast Cancer susceptibility genes: BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function) * At least one lesion that can be accurately assessed at baseline by CT/MRI and is suitable for repeated assessment. * Patients must have received at least 2 prior platinum based lines of chemotherapy - Patients must be partially platinum sensitive or platinum sensitive * Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice * Patients must have normal organ and bone marrow function measured within 28 days of randomisation, * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Patients must have a life expectancy ≥ 16 weeks * Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing. Exclusion Criteria: * BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental * Exposure to any investigational product wit…